Literature DB >> 8254616

Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives.

N J Hales1, J F Beattie.   

Abstract

Members of a series of 2,2'-bipyridines have been synthesized and tested as inhibitors of prolyl hydroxylase (EC 1.14.11.2). The structure-activity relationships seen with [2,2'-bipyridine]-5-carboxylic acid (4) closely resemble those of pyridine-2-carboxylic acid (2). Accordingly, [2,2'-bipyridine]-5,5'-dicarboxylic acid (11, IC50 = 0.19 microM) is the most potent inhibitor of its type yet reported. However, 2,2'-bipyridines lacking a 5-carboxylate are poor inhibitors. These contrasting structure-activity relationships are discussed in terms of net anionic charge, iron chelation, and the availability of alternative putative binding modes at a single binding site in each catalytic subunit.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254616     DOI: 10.1021/jm00076a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Inhibition of histone demethylases by 4-carboxy-2,2'-bipyridyl compounds.

Authors:  Kai-Hsuan Chang; Oliver N F King; Anthony Tumber; Esther C Y Woon; Tom D Heightman; Michael A McDonough; Christopher J Schofield; Nathan R Rose
Journal:  ChemMedChem       Date:  2011-03-15       Impact factor: 3.466

2.  A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.

Authors:  Banibrata Das; Subramanian Rajagopalan; Gnanada S Joshi; Liping Xu; Dan Luo; Julie K Andersen; Sokol V Todi; Aloke K Dutta
Journal:  Neuropharmacology       Date:  2017-05-19       Impact factor: 5.250

Review 3.  Collagen Prolyl 4-Hydroxylase as a Therapeutic Target.

Authors:  James D Vasta; Ronald T Raines
Journal:  J Med Chem       Date:  2018-07-23       Impact factor: 7.446

4.  Selective inhibition of prolyl 4-hydroxylases by bipyridinedicarboxylates.

Authors:  James D Vasta; Ronald T Raines
Journal:  Bioorg Med Chem       Date:  2015-05-11       Impact factor: 3.641

5.  Human Collagen Prolyl 4-Hydroxylase Is Activated by Ligands for Its Iron Center.

Authors:  James D Vasta; Ronald T Raines
Journal:  Biochemistry       Date:  2016-05-31       Impact factor: 3.162

6.  Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation.

Authors:  Mario Thevis; Maxie Kohler; Nils Schlörer; Wilhelm Schänzer
Journal:  J Am Soc Mass Spectrom       Date:  2007-11-09       Impact factor: 3.109

7.  Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors.

Authors:  Irina N Gaisina; Sue H Lee; Navneet A Kaidery; Manel Ben Aissa; Manuj Ahuja; Natalya N Smirnova; Sushama Wakade; Arsen Gaisin; Megan W Bourassa; Rajiv R Ratan; Sergey V Nikulin; Andrey A Poloznikov; Bobby Thomas; Gregory R J Thatcher; Irina G Gazaryan
Journal:  ACS Chem Neurosci       Date:  2018-01-17       Impact factor: 4.418

8.  Selective Inhibition of Collagen Prolyl 4-Hydroxylase in Human Cells.

Authors:  James D Vasta; Kristen A Andersen; Kathryn M Deck; Christopher P Nizzi; Richard S Eisenstein; Ronald T Raines
Journal:  ACS Chem Biol       Date:  2015-11-19       Impact factor: 5.100

Review 9.  Targeting histone lysine demethylases - progress, challenges, and the future.

Authors:  Cyrille C Thinnes; Katherine S England; Akane Kawamura; Rasheduzzaman Chowdhury; Christopher J Schofield; Richard J Hopkinson
Journal:  Biochim Biophys Acta       Date:  2014-05-21

10.  Pharmacological Suppression of CNS Scarring by Deferoxamine Reduces Lesion Volume and Increases Regeneration in an In Vitro Model for Astroglial-Fibrotic Scarring and in Rat Spinal Cord Injury In Vivo.

Authors:  Christina Francisca Vogelaar; Brigitte König; Stefanie Krafft; Veronica Estrada; Nicole Brazda; Brigida Ziegler; Andreas Faissner; Hans Werner Müller
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.